Enveric Biosciences and Aries Science Technology Announce Key US Patent Issuance

Novel Treatment for Radiation Dermatitis Receives Patent Protection

Groundbreaking Collaboration and Clinical Development Plans Unveiled

Portland, Oregon – Aries Science Technology and Enveric Biosciences are thrilled to announce the official issuance of a key US patent related to the treatment of radiation dermatitis. This patent falls under the Aries license and represents a significant milestone in the development of novel neuroplastogens, a breakthrough class of drugs.

Enveric Biosciences, a renowned biotechnology company, specializes in developing these innovative neuroplastogens for treating various neurological conditions. The newly patented product, licensed to Aries, is a topical treatment specifically designed to address radiation dermatitis, a common side effect of radiation therapy.

Under the terms of their Licensing Agreement, Aries will assume responsibility for developing and marketing the patented product for clinical use. This collaboration leverages the strengths of both companies, combining Aries' extensive clinical development capabilities with Enveric's scientific expertise in neuroplastogens.

Radiation dermatitis is characterized by skin inflammation, redness, and pain, often occurring during or after radiation therapy for cancer. The patented treatment, developed by Enveric, holds promise as a safe and effective solution to mitigate these debilitating effects.

This patent issuance strengthens the intellectual property portfolio of both Aries and Enveric and further validates the transformative potential of neuroplastogens in various therapeutic applications. The companies remain committed to advancing the clinical development of this promising treatment and bringing it to patients in need.